This paper is based on a Cochrane review published in The Cochrane Library, issue 2, 2001 (see www.CochraneLibrary. net for information) with permission from The Cochrane Collaboration and Update Software. Cochrane reviews are regularly updated as new evidence emerges and in response to comments and criticisms, and The Cochrane Library should be consulted for the most recent version of the review.
Introduction
Polycystic ovary syndrome (PCOS) is the most common cause of female anovulatory infertility. To induce ovulation, clomiphene citrate (CC) is the ®rst line of treatment. However, about 20% of women are resistant to CC and require gonadotrophin therapy (Hull, 1987) . Since 1958 these women have been treated with FSH, originally extracted from pituitary glands (Gemzell et al., 1958) and later extracted from postmenopausal urine (Lunenfeld et al., 1960) .
Over the last four decades, various urinary FSH (uFSH) products have been developed. Menotropin (HMGs), available since the early 1960s, contains FSH, LH and large quantities of potentially allergenic urinary proteins. Urofollitropin (FSH), available since the mid-1980s, is devoid of LH, but is still contaminated with urinary proteins. Highly puri®ed Urofollitropin (FSH-HP), available since the mid-1990s, contains very small amounts of urinary proteins. Lack of urinary proteins diminishes adverse reactions such as local allergy or hypersensitivity (Biffoni et al., 1994; Albano et al., 1996) , while the absence of LH has no negative in¯uence on stimulation of PCOS patients (van Weissenbruch et al., 1993; Hayden et al., 1999) .
To obtain higher purity, complete absence of LH and copuri®ed proteins, high speci®c bioactivity (roughly 100 times higher than for urine-derived FSH products), independence of urine collection, absolute source control and batch-to-batch consistency, recombinant FSH (rFSH) was synthesized in 1988. This was realized by transfecting Chinese hamster ovary cell lines with both FSH subunit genes Keene et al., 1989) .
At present, two preparations of rFSH are available: follitropin alpha (Gonal F â ), marketed in 1995, and followed by follitropin beta (Puregon â ) soon after. Both preparations are similar to pituitary FSH and uFSH, although they show minor differences in the structure of the carbohydrate side chains and contain more basic and less acidic isohormones than the natural hormones (Hard et al., 1990; de Leeuw et al., 1996) .
Ovulation induction with FSH bears the risk of multiple follicle development, multiple pregnancies and ovarian stimulation syndrome (OSS) (Wang and Gemzell, 1980; Garcea et al., 1985; Neyro et al., 1991) . To reduce these complications, various dose regimen strategies have been used (Brown et al., 1969; Lunenfeld and Insler, 1974; Hamilton-Fairley et al., 1991; Shoham et al., 1991; Fauser et al., 1993; Balen et al., 1994) .
At present, the most frequently used administration schedules are the low dose step-up and step-down regimens. For uFSH it was shown that a low dose step-up protocol has the advantage of a more controlled stimulation, resulting in less development of multiple follicles and therefore a decreased risk of OSS and multiple pregnancies (Homburg and Howles, 1999) .
In a previous Cochrane review the effectiveness of urinary gonadotrophins in PCOS was studied Nugent et al., 2000) . Urinary-derived FSH preparations did not improve pregnancy rates when compared with traditional and less expensive HMG preparations. However, the use of uFSH did result in a reduced risk of OSS.
The objective of this review was twofold. First, to assess the ef®cacy and safety of rFSH for ovulation induction in women with PCOS as compared with uFSH, and secondly, to assess the ef®cacy and safety of different dose regimens of rFSH.
Materials and methods
This paper is based on a Cochrane review published in The Cochrane Library 2001, Issue 2 (see www.CochraneLibrary.net for information). The review has drawn on the search strategy developed for the Cochrane Menstrual Disorders and Subfertility Group as a whole. Relevant trials were identi®ed from the Trial Register of the Review Group and the electronic databases MEDLINE and EmBASE were searched. The following keywords were used: polycystic ovary syndrome, oligomenorrhoea, oligo-amenorrhoea, amenorrhoea, anovulation, ovulation induction, recombinant FSH and FSH.
Hand-searching of the references mentioned in the included trials was performed and citation lists of eligible studies, conference abstracts and relevant review articles were examined as well. Serono Benelux BV and NV Organon, the manufacturers of follitropin alpha (Gonal F â ) and follitropin beta (Puregon â ) respectively, were asked for ongoing studies and unpublished data.
Only truly randomized controlled trials comparing rFSH and uFSH or different treatment modalities of rFSH for ovulation induction in women with PCOS, and specifying at least the clinical pregnancy rate per woman, were eligible for this review.
Institutional Review Board approval was not required for this metaanalysis of previously published and unpublished clinical trials.
The preferable primary outcome measure is live birth or ongoing pregnancy per woman. As this outcome was not evaluated in all eligible trials, clinical pregnancy rate per woman was chosen as primary outcome. Secondary outcomes included ovulation rate per cycle and ongoing pregnancy rate, live birth, miscarriage rate, incidence of OSS, incidence of multiple pregnancy, total gonadotrophin dose, total duration of stimulation, single follicle development and cancellation rate per woman.
The selection of trials for inclusion in the review was performed independently by two reviewers (M.v.W. and N.B.) after employing the search strategy described previously. The search strategy yielded six randomized controlled trials eligible for inclusion. Included studies were assessed independently for prede®ned quality criteria and methodological details (Table I) .
Two reviewers (M.v.W. and N.B.) independently extracted the data. All data were entered into the Review Manager (RevMan 4.0.4) computer software (Update Software, Oxford, UK) and doublechecked for accuracy. When crossover studies were identi®ed, only data from the pre-crossover period were included in the review.
Additional information on trial data was sought by contacting the corresponding author when data were in a form unsuitable for metaanalysis. Statistical analysis was performed in accordance with the guidelines developed by the Cochrane Menstrual Disorders and Subfertility Group (1999) . For dichotomous data, odds ratios (ORs) with 95% con®dence intervals (CIs) were calculated for each individual trial using the Peto modi®cation of the Mantel±Haenszel method (Peto, 1987) . For continuous data the weighted mean difference (WMD) was calculated. When median and range were given instead of mean and SD, the mean was estimated by logarithmic transformation of the minimum and maximum values and the SD was imputed from the overall SD of the other studies. In the absence of heterogeneity of treatment effect among trials, which was tested using the Breslow±Day c 2 -test, the data were pooled. For pooled dichotomous data an overall combined OR with 95% CIs was calculated using the Peto method and for continuous data a WMD with 95% CIs was calculated using the inverse variance method. Negative values in WMD indicate a bene®t of rFSH over uFSH.
Results
This review identi®ed six trials that met the inclusion criteria (Loumaye et al., 1996; Coelingh Bennink et al., 1998; Hedon et al., 1998; Yarali et al., 1999; Balasch et al., 2000; 2001) . Three trials with a total of 457 women compared rFSH with uFSH (Loumaye et al., 1996; Coelingh Bennink et al., 1998; Yarali et al., 1999) . A further three trials compared different treatment regimens using rFSH. The number of included patients in these trials were 103 (Hedon et al., 1998) , 15 (Balasch et al., 2000) and 26 (Balasch et al., 2001) . All trials were fully published in peer-reviewed journals except for one study (Loumaye et al., 1996) , which was described in a review on human gonadotrophins produced by recombinant DNA technology. Additional data on this trial were obtained by personal communication (E.Loumaye).
The participants in all six trials were CC-resistant, anovulatory women. CC resistance was generally de®ned as failure to ovulate on doses of CC up to 150 or 200 mg/day, or failure to conceive with the ovulatory dose of CC during three to six previous cycles (Coelingh Bennink et al., 1998; Yarali et al., 1999; Balasch et al., 2000; 2001) . Two trials did not give a de®nition of CC resistance (Loumaye et al., 1996; Hedon et al., 1998) . A detailed description of the six trials included in this review is given in Table I .
All six trials included were randomized controlled studies. Three were single centre (Yarali et al., 1999; Balasch et al., 2000; 2001) and the other three were multicentre studies (Loumaye et al., 1996; Coelingh Bennink et al., 1998; Hedon et al., 1998) . Three studies used a randomization list that Infertile women with WHO II group anovulation, resistant to CC. Mean age (TSD) of the women was 27.8 (4.8) years for the uFSH and 30.0 (5.8) years for the rFSH group. Body mass index (TSD) was 27.1 (5.5) and 27.1 (3.7) for rFSH and uFSH, respectively. Duration of infertility (TSD) was 7.0 (5.6) years and 9.0 (4.2) years for rFSH and uFSH, respectively. LH:FSH ratio was 2.4:1.3 for the uFSH and 3.4:5.5 for the rFSH group. Testosterone level (TSD) (ng/ml) was 0.9 (0.4) and 0.97 (0.9) for rFSH and uFSH, respectively. uFSH (Metrodin â ) versus rFSH (Gonal F â ). Treatment was started between day 3 and day 5 of a spontaneous or induced menses. Low dose step-up protocol was used. Starting dose was 75 IU uFSH (i.m.)/day or rFSH (s.c)/day up to 14 days, unless follicle maturity was reached. If no ovarian response was noted the dose was increased by half an ampoule every week to a maximum of 225 IU/day. Treatment was discontinued after 35 days of treatment. HCG (10 000 IU, Profasi) was given when a follicle of at least 17 mm was seen. CC-resistant WHO Group II anovulatory women. Mean age (TSD) of the patients was 29.4 (4.3) years in the chronic low dose and 29.7 (4.0) years in the conventional group. Body mass index (TSD) was 22.6 (4.7) and 22.7 (3.7) for chronic low dose and conventional respectively. Duration of infertility (TSD) was 3.4(1.9) years in the chronic low dose and 2.9(1.5) years in the conventional group. Primary infertility was 73.6 and 74%, respectively. Infertility work up consisted endocrinology (LH, FSH, progesterone), hysterosalpingography, or hysterosalpingoscopy and semen analysis.
Chronic low dose versus conventional stimulation of rFSH (Gonal-F â ). Treatment started between day 3 and day 5 of an induced or spontaneous menses. Starting dose was 75 IU rFSH (s.c.)/day. Chronic low dose protocol: the starting dose was maintained up to 14 days unless follicle maturity was reached. If no ovarian response was noted after this period the dose was increased with 37.5 IU/day weekly. Conventional protocol: the starting dose was increased 75 IU every 5 days from day 7 of stimulation depending on ovarian response. Treatment was discontinued after 35 days of treatment or if the patient was at risk of OSS. HCG (5000 IU, Profasi) was given when a follicle of 16 mm developed. CC-resistant, chronic anovulatory patients with polycystic ovaries on ultrasound scan. Baseline characteristics for whole group only. Mean age (TSE) of the patients was 34.1 (0.9) years. Body mass index (TSE) was 24.6 (0.5). Duration of infertility (TSE) was 4.4 (1.3) years. Number of subjects with primary infertility was not given. The mean (SE) LH/FSH ratio was 2.5 (0.2).
Chronic low dose step-up stimulation with two starting doses of rFSH (Gonal-F â or Puregon â ). Treatment was started at day 3 of an induced or spontaneous menses. Starting dose was 37.5 or 75 IU rFSH (s.c.)/day. The starting dose was maintained up to 14 days, unless follicle maturity was reached. If no ovarian response was noted after this period the dose was increased with 37.5 IU/day and 50 IU, respectively. Further dose adjustments after 7 days if necessary. HCG (10 000 IU, Profasi) was given when a follicle >17 mm developed. rFSH in alternative doses or versus uFSH in PCOS corresponded with patient drug codes (Loumaye et al., 1996; Coelingh Bennink et al., 1998; Hedon et al., 1998) , one used computerized allocation strati®ed by centre (Hedon et al., 1998) and for two studies the method of randomization is unknown (Balasch et al., 2000; 2001) . Only one study performed a power calculation (Loumaye et al., 1996) . None of the other ®ve trials reported a sample size with power calculation. An intention-to-treat analysis was performed only in one trial (Coelingh Bennink et al., 1998) . This trial also was assessor-blind, whereas the other three were open-label. Double-blinding should have been possible for the three trials comparing rFSH with uFSH, but this was not done as rFSH was supplied in vials and uFSH in ampoules.
Withdrawals after randomization were mentioned in all trials. In the three trials comparing rFSH with uFSH women were treated for a maximum of three cycles. For these trials no information was present on losses to follow-up after the ®rst cycle. Only three studies gave information on duration and timing of the trial (Coelingh Bennink et al., 1998; Hedon et al., 1998; Yarali et al., 1999) . Of the trials comparing different dose regimens, two were crossover trials (Balasch et al., 2000; 2001) .
Outcomes
Figure 1 summarizes all dichotomous outcomes for the three trials comparing rFSH with uFSH. Trial results could be combined for ®ve outcomes. There was no evidence for statistical heterogeneity. Most outcomes differed between the trials. The clinical pregnancy rate for example was 42% after rFSH and 48% after uFSH in one trial (Loumaye et al., 1996) , 30% after rFSH and 28% after uFSH in the second trial (Coelingh Bennink et al., 1998) , and 50% after rFSH and 37% after uFSH in the third trial (Yarali et al., 1999) . Pooling the data for clinical pregnancy per woman resulted in an OR of 0.95 (95% CI 0.64±1.41) for rFSH versus uFSH.
Only one trial comparing rFSH with uFSH reported data on ongoing pregnancy (Coelingh Bennink et al., 1998) and none of the trials reported data on live birth. There was no evidence of a difference between hMG and rFSH in clinical pregnancy, Chronic low dose step up versus a modi®ed step-down stimulation with rFSH (Gonal-F â ). Treatment was started at day 3 of an induced or spontaneous menses. Chronic low dose step-up protocol: The starting dose of 75 IU rFSH (s.c.)/day. was maintained up to 14 days, unless follicle maturity was reached. If no ovarian response was noted after this period the dose was increased with 37.5 IU/day weekly. Modi®ed step-down protocol: The starting dose was 300 IU on cycle day 3 and no treatment was given on the next 3 days. On treatment day 5 rFSH was given as 75 IU/day. This dose was maintained for 2 days. The subsequent treatment protocol followed the low dose step-up approach. 10 000 IU HCG (Profasi) was given when a follicle >17 mm developed. ongoing pregnancy, ovulation, miscarriage, OSS, multiple pregnancy and cancellation rate. Table II summarizes the continuous outcomes for the trials comparing rFSH with uFSH. The weighted means for the total FSH dose used, duration of stimulation and estradiol (E 2 ) level on the day of HCG administration did not differ signi®cantly between rFSH and uFSH. As different measures for number of follicles were used (i.e. 10±12, 10±14 mm) these data could not be pooled and the separate results are not conclusive.
For the three trials that compared different treatment regimes of rFSH no trial results could be combined, as each trial compared a different treatment regimen. Table III summarizes the dichotomous outcomes for these trials. One trial compared chronic low dose step-up with conventional rFSH stimulation (Hedon et al., 1998) . There was insuf®cient evidence of a difference in ovulation, clinical pregnancy, live birth, miscarriage, OSS, multiple pregnancy, FSH dose and duration of stimulation for chronic low dose step-up versus conventional Table II . Summary data of secondary continuous outcomes for rFSH versus uFSH (Coelingh Bennink et al., 1998; Yarali et al., 1999) CLD starting dose 37.5 versus 50 IU (Balasch et al., 2000) 37
Clinical pregnancy (per woman) 3/12 (25) 3/10 (33) 0.79 0.12±4.96
Modi®ed step-down versus CLD (Balasch et al., 2001) Step (Table IV) . Another trial (Balasch et al., 2001 ) compared a modi®ed step-down with a chronic low dose step-up protocol for rFSH stimulation. Pre-crossover data could only be recovered for ovulation and clinical pregnancy. All women ovulated in the ®rst cycle before actual crossover. The OR for clinical pregnancy per woman was 1.9 (95% CI 0.18±19.98) for the modi®ed step-down versus chronic low dose step-up protocol.
The third trial (Balasch et al., 2000) compared a starting dose of 37.5 IU with 50 IU in a chronic low dose step-up protocol for rFSH stimulation. Pre-crossover data could only be recovered for ovulation and clinical pregnancy. All women ovulated in the ®rst cycle before actual crossover. The OR for clinical pregnancy per woman was 0.79 (95% CI 0.12±4.96) for 37.5 versus 50 IU.
Discussion
In this systematic review of randomized controlled trials there was no evidence of a difference in ef®cacy and safety between rFSH and uFSH. Gonadotrophins used in these studies were Follitropin beta (Puregon â ) versus Urofollitropin (Metrodin â ) (Coelingh Bennink et al., 1998) and Follitropin alpha (Gonal F â ) versus Urofollitropin (Metrodin â ) (Loumaye et al., 1996; Yarali et al., 1999) . Pooling the data from these three studies was only possible for pregnancy rate (OR 0.95, 95% CI 0.64±1.41), multiple pregnancy rate (OR 0.44, 95% CI 0.16±1.21), miscarriage rate (OR 1.26, 95% CI 0.59±2.70) and OSS (OR 1.55, 95% CI 0.50±4.84). For the following outcomes only two studies (Coelingh Bennink et al., 1998; Yarali et al., 1999) could be pooled: ovulation rate per cycle (OR 1.19, 95% CI 0.78±1.80), mean total FSH dose (IU) used (WMD ±171, 95% CI ±650, 308), mean duration of stimulation (WMD ±1.99 days, 95% CI ±4.51, 0.54) and mean E 2 level used on day of HCG administration (WMD ±9.1, 95% CI ±110.6, 92.5). All trials comparing rFSH with uFSH used a chronic low dose scheme.
Another trial compared chronic low dose with a conventional regimen using Follitropin alfa (Gonal F â ) (Hedon et al., 1998) . In this comparison a difference in favour of chronic low dose regimen was found for clinical pregnancy rate (OR 1.62, 95% CI 0.64±4.07), miscarriage rate (OR 0.62, 95% CI 0.03±11.34) and multiple pregnancy rate (OR 0.59, 95% CI 0.07±5.12), although these differences did not reach statistical signi®cance, which might be because of the fact that these results are based upon a small population size of 103 women. Ovulation rate was similar (OR 0.95, 95% CI 0.43±2.06) in both groups.
This stimulation regimen with a low starting dose and small stepwise increments in dosage has been introduced to prevent the development of multiple follicles and therefore of multiple pregnancies and OSS. Indeed, in women treated with a chronic low dose, signi®cantly less follicles >10 mm and a lower level of E 2 on the day of HCG administration were found compared with women treated with the conventional regimen (Hedon et al., 1998) . Similar ®ndings were observed in a review that included 11 studies comparing chronic low dose with conventional regimens of uFSH (Homburg and Howles, 1999) . Therefore, chronic low dose regimens appear to be preferable above the conventional regimens for both uFSH and rFSH.
The two further trials that compared, respectively, a modi®ed step-down with a chronic low dose step-up protocol and two starting doses of rFSH in a chronic low dose step-up protocol were very small crossover studies that do not permit any conclusions to be drawn (Balasch et al., 2000; 2001) .
When comparing the effectiveness of rFSH and uFSH the bioactivity of these gonadotrophins is of interest. The glycoform distribution of rFSH is most basic. In that sense, Urofollitropin resembles rFSH more closely than highly puri®ed Urofollitropin, as the last is more acidic (Lambert et al., 1995) . The more basic preparations would have a higher biopotency (Lambert et al., 1995) .
Several parameters are commonly used as indicators for the bioactivity of FSH: number of follicles >12 mm, E 2 level on the day of hCG administration, total dose of FSH required to induce follicular development and the duration of stimulation. Indeed, one of the included studies found signi®cantly more follicles in the range of 12±14 mm in the rFSH group, although this was not found for follicles >15 mm (Coelingh Bennink et al., 1998) . Furthermore, rFSH required a signi®cantly shorter treatment period to induce ovulation in the ®rst cycle. There was no proof of a difference in mean E 2 level and total dose required between rFSH and uFSH. One other trial also studied the indicators for bioactivity mentioned above (Yarali et al., 1999) . This trial, however, found no difference in number of follicles in the range of 10±14 mm, but did ®nd signi®cantly less follicles >14 mm in the rFSH group. No differences were observed in E 2 level, total FSH dose and treatment period required to induce ovulation. Based on these two studies it therefore cannot be determined whether rFSH has a higher bioactivity than uFSH in ovulation induction.
In ovulation induction the main goal is to achieve maturation and ovulation of a minimal number of follicles, preferable one, to obtain a singleton pregnancy without OSS. A higher bioactivity of rFSH in ovulation induction is therefore only bene®cial when this is translated into a lower total dose and a shorter duration of stimulation.
If the use of rFSH would lead to a low dosage requirement and short stimulation duration in ovulation induction, it is still questionable whether rFSH is also more cost effective, as rFSH is more expensive than uFSH. In summary, there is as yet insuf®cient evidence to conclude that rFSH is more effective than uFSH for ovulation induction in women with CC-resistant PCOS. More randomized clinical trials with suf®cient power are necessary to estimate the difference between hMG and rFSH, if one exists. Evaluations of the outcomes should relate to ef®cacy parameters, as well as to adverse effects and costeffectiveness analyses.
